Business

Exelixis' cabozantinib reduces lung and thymic NET progression risk by 81%

Oct 18, 2025 - 09:00
 0
Exelixis' cabozantinib reduces lung and thymic NET progression risk by 81%
Read More

Related Posts

The five keys to unlock homeownership for emerging buyers

The five keys to unlock homeownership for emerging buyers

Mar 21, 2025  0

ZipRecruiter SVP Bartolome Lora sells $12,861 in shares

ZipRecruiter SVP Bartolome Lora sells $12,861 in shares

Mar 21, 2025  1

Atea Pharmaceuticals Issues Statement Regarding Director Nominations

Atea Pharmaceuticals Issues Statement Regarding Directo...

Mar 21, 2025  3

ZipRecruiter president David Travers sells $106,161 in stock

ZipRecruiter president David Travers sells $106,161 in ...

Mar 21, 2025  0

Meta global affairs chief says decision not to offer Instagram, Facebook in China helps defend free expression

Meta global affairs chief says decision not to offer In...

Mar 21, 2025  3

ZipRecruiter CTO Boris Shimanovsky sells $22,788 in stock

ZipRecruiter CTO Boris Shimanovsky sells $22,788 in stock

Mar 21, 2025  0